WHO HE IS

• A history-making scientist rewriting what medicine can do.

• Kiran Musunuru is among the few doctors in the world turning gene editing into real medicine – not theory, not trials, but lives saved.

• With the historic case of KJ Baby, he’s ushered us into the era of ‘precision medicine.’

THE BOY WHO LIVED: KJ BABY

• A nine-month-old KJ was diagnosed with an ultra-rare genetic disease called the CPS1 deficiency.

• Baby KJ’s liver couldn’t process ammonia – a toxin produced every time the body processes protein. It built up in his blood and organ failure was imminent. There was no approved treatment. No drug pipeline. No time. Baby KJ was dying fast.

• Musunuru co-designed the world’s first fully personalized gene-editing therapy delivered inside the human body – crafted not for a disease category, but for one infant’s DNA.

• Doctors corrected the fatal genetic error. KJ’s metabolism normalised. And a child who was expected to die, lived.

• The case was published in The New England Journal of Medicine. And instantly entered medical history.

THE METHOD & WHY IT MATTERS

• This was not a mass-market drug. It was medicine engineered for one child, one genome.

• Instead of cutting DNA, Musunuru’s approach relies on base editing – chemical swaps at single DNA letters. Think typo correction, not page tearing.

• The promise: fewer unintended effects, greater precision, and clinical feasibility.

• The human genome is a scroll of 6.4 billion letters, origami-ed into each cell of our body. Glitch in even a single letter can translate into 10,000+ diseases. 

• So the idea that a single letter can be corrected to fix a genetic error, and customise cure for an individual, is sci-fi coming to life.

• Musunuru’s work exemplifies the shift from scattershot medicine – one-size-fits-all drugs, decades-long clinical trials, and lifelong dosing – to the possibility of medicine now tailored to a person’s unique biology.

WHAT COMES NEXT

• Across the world, heart attacks are striking younger people in their 30s and 40s. In India, 25% of all deaths are caused by cardiovascular diseases.

• At a time like this, Musunuru is asking an audacious question: What if heart disease didn’t need lifelong pills? What if risk could be shut off once?

• A cardiologist by training, he’s using CRISPR – the genetic equivalent of molecular scissors – to go after disease at its source, not its symptoms.

• Drugs work, but only as long as patients keep taking them. The ambition of Kiran’s work is staggering: his work explores a one-time vaccination against heart diseases. No daily compliance. No slow decline. One intervention. Permanent reset.

CURE vs DESIGN

• While the world is applauding the therapeutic use, the ethics are already on fire.

• Because the same tool, CRISPR, that saved KJ could one day be used to enhance traits – blue eyes, taller height, leaner frames, higher IQ, lower appetite. “I think of CRISPR like fire. If you control fire, you can cook food or keep warm. But if you don’t have good control, it can do very bad things. It can burn down the house or cause a wildfire that burns down a whole town,” said Musunuru.

• History has already shown what happens when restraint fails. In 2018, He Jiankui shocked the world by editing the genes of human embryos and implanted them back in their mother. Twin girls, Lulu and Nana, with edited genes were born. Jiankui wound up in jail for what he did, triggering global outrage and a scientific reckoning over how far is too far.

• Musunuru has been explicit about this line: “I can easily imagine parents wanting to make changes they feel are beneficial for their babies, things you might consider enhancements. This could be frivolous things, such as hair color or eye color, or it could be intelligence or athletic ability.”

WHO GETS THE UPGRADE?

• Custom gene edits are astronomically expensive – often running into the millions of dollars per patient.

• If cures are custom-built, who gets them? Who decides what’s worth fixing? And will genetic salvation become the privilege of the wealthy?

• Will this build a new race, a new class, a new kind: superhumans?

• Musunuru’s scholarship sits squarely inside this tension: extraordinary power, unresolved responsibility.

AT SYNAPSE

Kiran Musunuru will show how a sci-fi vision of medicine is becoming clinical reality. How custom gene edits are already saving lives. Why the success of one child matters to millions. And why the line between healing and enhancement may become the most contested frontier in human biology.

Previous Next